NEW! Azide Activation of Human IgG using TransGLYCIT Azide Activation
We're happy and proud to announce the launch of TransGLYCIT Azide Activation!
Blog
Welcome to our blog! This is where we share a bit more – insights, updates, and thoughts from Genovis. Take a look around and see what you find.
Search post
Category
NEW! PNGase F for Hydrolysis of N-glycans
We are happy to announce that PNGase F for in-solution hydrolysis of N-glycans from glycoproteins is added to our portfolio of SmartEnzymes!
NEW FabDELLO – The SmartEnzyme for Mutated IgG
We introduce FabDELLO, a protease that specifically digests human IgG1 at a single site above the hinge, generating intact Fab and Fc fragments within two hours with no need for reducing conditions. The enzyme is active on antibodies with mutated hinge regions and enables middle-level LC-MS for characterization of critical quality attributes.
NEW SmartEnzyme – Immobilized PNGase F for Fast N-glycan Hydrolysis!
Genovis launches Immobilized PNGase F, a resin with the PNGase F enzyme covalently coupled to agarose beads for hydrolysis of N-glycans on antibodies, fusion proteins and other N-glycosylated proteins in a convenient spin column format.
NEW TransGLYCIT™ Glycoforms Available!
Genovis launches new glycoforms with TransGLYCIT™ - A platform to create IgG with defined glycan profiles! TransGLYCIT enables specific IgG N-glycan remodeling and prepares antibodies with a defined and homogenous G0, G1, G2 or G2S2 glycoform using fast and robust enzymatic workflows. With the optional FucosEXO™ 16 enzyme, afucosylated antibodies can be obtained that enable…
New Application Note on Antibody Oxidation Analysis
A Rapid LC-MS Assay for Monitoring of mAb Oxidation at the Subunit Level Methionine oxidation is considered a critical quality attribute of therapeutic antibodies and may impact the clinical safety and efficacy. Therefore, monitoring of methionine oxidations is required during the discovery, development, and production of therapeutic antibodies. Traditional methods to characterize oxidation rely…
Launching New Anti-FabRICATOR Formats!
We are happy to announce two new affinity purified antibody formats for detecting the FabRICATOR enzyme! The Anti-FabRICATOR Affinity Purified is an affinity purified goat polyclonal antibody and the Anti-FabRICATOR Affinity Purified Biotin Conjugated is an affinity purified and biotin-conjugated goat polyclonal antibody.
Characterization of SARS-CoV-2 Receptor-Binding Domains using SmartEnzymes™
Scientists at Leiden University Medical Center (LUMC) present a multilevel mass spectrometry approach using SmartEnzymes for in-depth characterization of mammalian SARS-CoV-2 receptor-binding (RBD) domains. The COVID-19 disease caused by the SARS-CoV-2 virus has affected more that 100 million individuals in the ongoing pandemic. The enveloped RNA corona virus contains three structural proteins in the…
Genovis Teams up with Waters to Deliver Enzymatic Workflows for the Biopharma Industry
The new collaboration between Genovis and Waters Corporation is intended to bring fast and easy analytical workflows for biopharmaceuticals by combining the SmartEnzymes™ portfolio from Genovis with the unique instrumentation from Waters™. The lab work has already started, and we got a quick word with Andreas Nägeli, one of the scientists at Genovis contributing to…
NEW SmartEnzymes – Launching FucosEXO!
Genovis launches FucosEXO, an α-fucosidase mix for efficient removal of α1-2, α1-3 and α1-4 linked Fucose on native N- and O-glycosylated proteins. Analysis of glycoproteins modified with complex glycan structures can be challenging and requires efficient and specific enzymatic tools. FucosEXO is a mix of α-fucosidases for efficient hydrolysis of α1-2, α1-3 and α1-4…
Genovis receives funding from Vinnova
Genovis receives funding from Vinnova for the development of a new high-throughput platform for a directed and efficient product development for quality assurance of biological drugs. To understand the project we got a quick word with the VP of Research & Development at Genovis, Rolf Lood. Rolf is heading the enzyme discovery team at Genovis…
SmartEnzymes in Targeted Sequencing of Heavily Glycosylated IgA1
The use of IgG-based antibodies in various clinical fields have increased over that past decades, continuing the development of better biopharmaceuticals. The use of other immunoglobulins including IgA, characterized with the ability to recruit effector cells, is progressively being considered a useful alternative. The complexity of the heavily glycosylated IgA does however pose analytical challenges…
